Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections

PHASE3RecruitingINTERVENTIONAL
Enrollment

4,514

Participants

Timeline

Start Date

December 27, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

August 31, 2025

Conditions
Surgical Site InfectionsSurgical Wound InfectionInfectionsAnti-Infective Agents
Interventions
COMBINATION_PRODUCT

nasal antimicrobial photodisinfection therapy

Application of NF-031 solution (methylene blue 0.01% USP (methylthioninium chloride) and 0.25% chlorhexidine gluconate) in the nares followed by 2-minutes of light with nasal illuminators. The application is repeated a second time for total treatment time of 5-minutes.

Trial Locations (16)

23235

NOT_YET_RECRUITING

Johnston Willis Hospital, Richmond

33511

RECRUITING

HCA Brandon Florida, Brandon

33709

RECRUITING

HCA Florida NorthSide Hospital, St. Petersburg

33770

RECRUITING

HCA Florida Largo Hospital, Largo

34655

RECRUITING

HCA Florida Trinity Hospital, Trinity

37203

RECRUITING

Centennial Medical Center, Nashville

75034

RECRUITING

Medical City Frisco Hospital, Frisco

75075

RECRUITING

Medical City Plano, Plano

75230

RECRUITING

Medical City Dallas, Dallas

RECRUITING

Medical City Heart and Spine Hospital, Dallas

77339

RECRUITING

HCA Houston Healthcare Kingwood, Kingwood

77598

RECRUITING

HCA Houston Healthcare Clear Lake Hospital, Webster

78212

NOT_YET_RECRUITING

Methodist Metropolitan Hospital, San Antonio

78229

RECRUITING

Methodist Main Hospital, San Antonio

78258

RECRUITING

Methodist Stone Oak, San Antonio

80113

RECRUITING

Swedish Medical Center, Englewood

Sponsors
All Listed Sponsors
lead

Ondine Biomedical Inc.

INDUSTRY

NCT06702878 - Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections | Biotech Hunter | Biotech Hunter